11 completed, 3 terminated, 2 withdrawn. 13 Phase 1, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Withdrawn 2 |
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow lanabecestat: new trials by email Literature Review of lanabecestat trials Research Report on lanabecestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants Lanabecestat, Iohexol - Renal Insufficiency | Phase 1 | Withdrawn | Eli Lilly and Company | 2018-06-01 | 2018-06-28 | |
| A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive Lanabecestat, Oral Contraceptive - Healthy | Phase 1 | Withdrawn | Eli Lilly and Company | 2018-06-01 | 2018-06-28 | |
| A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia Lanabecestat - Alzheimer's Disease | Phase 3 | Terminated | AstraZeneca | 421 | 2017-03-15 | 2019-12-03 |
| A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin Lanabecestat, Rosuvastatin - Healthy | Phase 1 | Completed | AstraZeneca | 42 | 2017-01-12 | 2019-11-01 |
| A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia Lanabecestat, Placebo - Alzheimer's Disease | Phase 3 | Terminated | AstraZeneca | 1722 | 2016-07-01 | 2019-12-03 |
| A Study of Lanabecestat (LY3314814) in Healthy Participants Lanabecestat - Healthy | Phase 1 | Completed | AstraZeneca | 18 | 2016-01-31 | 2019-11-01 |
| A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants Lanabecestat, Dabigatran etexilate - Healthy | Phase 1 | Completed | AstraZeneca | 60 | 2015-10-31 | 2019-11-01 |
| A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants Lanabecestat, Warfarin - Healthy | Phase 1 | Completed | AstraZeneca | 15 | 2015-09-30 | 2019-11-04 |
| A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants Lanabecestat, Simvastatin, Midazolam - Healthy | Phase 1 | Completed | AstraZeneca | 82 | 2015-04-30 | 2019-11-04 |
| An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Lanabecestat, Placebo - Alzheimer´s Disease | Phase 2 / Phase 3 | Terminated | AstraZeneca | 2218 | 2014-09-30 | 2019-12-03 |
| A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 AZD3293 - Healthy Volunteers, Mass Balance Study | Phase 1 | Completed | AstraZeneca | 12 | 2014-05-01 | 2014-06-16 |
| Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects AZD3293 oral solution, AZD3293 tablet formulation A, AZD3293 tablet formulation B - Healthy Volunteers, Pharmacologic Action | Phase 1 | Completed | AstraZeneca | 1 | 2014-02-01 | 2014-04-24 |
| AZD3293 Thorough QT Study in Healthy Male Volunteers AZD3293, Placebo, Moxifloxacin - Alzheimer's Disease | Phase 1 | Completed | AstraZeneca | 52 | 2014-01-01 | 2014-07-03 |
| A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers AZD3293, Placebo - Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers | Phase 1 | Completed | AstraZeneca | 114 | 2013-12-01 | 2016-11-04 |
| A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients AZD3293, Placebo - Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients | Phase 1 | Completed | AstraZeneca | 47 | 2013-03-01 | 2014-04-03 |
| A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects AZD3293, Placebo - Healthy Young Volunteers, Healthy Elderly Volunteers | Phase 1 | Completed | AstraZeneca | 72 | 2012-12-01 | 2013-08-27 |
Alzheimer Disease (5) · Brain Diseases (3) · Central Nervous System Diseases (3) · Dementia (3) · Mental Disorders (3) · Nervous System Diseases (3) · Tauopathies (3) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Delirium (1) · Renal Insufficiency (1)
AstraZeneca (14) · Eli Lilly and Company (2)
United States (13) · Japan (4) · Canada (3) · France (3) · Germany (3) · Poland (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Hungary (2) · Italy (2) · Puerto Rico (2) · Romania (2)
Robert C Alexander, MD (3) · Ronald Goldwater, MD (2) · David Han, MD (1) · Irene Mirkin, MD (1) · Kei Sakamoto, MD, PhD (1)
PMID 27767991, PMID 31764959, PMID 29199322, PMID 33049114, PMID 40603145
2014 (1), 2015 (1), 2016 (1)